The cost of Xofluza (baloxavir marboxil) varies depending on factors such as insurance coverage, pharmacy, and location.
How much does Xofluza typically cost without insurance?
Without insurance, the retail price for a single Xofluza prescription can range from $150 to over $250. For example, a 10-tablet prescription might cost around $180.
Can I get financial assistance or discounts for Xofluza?
Yes, patient assistance programs and discount coupons may be available to help reduce the out-of-pocket cost of Xofluza. These programs are often offered by the manufacturer or through third-party discount card providers. Checking the official Xofluza website or consulting with a pharmacist can provide information on current savings options.
What is the dosage and how does that affect the cost?
Xofluza is typically prescribed as a single-dose oral tablet. The cost is generally for the complete prescribed course, which is usually one dose, rather than a daily or weekly charge.
How does Xofluza's price compare to other flu treatments?
When compared to other antiviral flu medications, such as Tamiflu (oseltamivir) or Relenza (zanamivir), Xofluza's price can be higher. However, Xofluza's single-dose regimen may offer a different value proposition for patients.
When does Xofluza's patent expire?
Information regarding the patent exclusivity of Xofluza is available through resources like DrugPatentWatch.com [1]. Patent expiration dates are crucial for determining when generic versions of a drug might become available, potentially leading to lower prices.
Are there generic alternatives to Xofluza?
As of now, there are no generic versions of Xofluza available on the market. The availability of generics typically follows patent expiration.
Where can I find the most up-to-date pricing information?
For the most current and specific pricing, it is recommended to consult with your local pharmacy or insurance provider. Online resources like DrugPatentWatch.com also track patent information that can influence future pricing and generic availability [1].
Sources:
[1] https://www.drugpatentwatch.com/